AstraZeneca, Pfizer rebuked over breaking UK drug marketing rules on LinkedIn use
The PMCPA has dug into the industry’s LinkedIn activities once again. AstraZeneca received the harshest censure in the latest set of cases, taking a telling-off over one of its own posts, while Pfizer escaped with a slap on the wrist after its employees got too liberal with their LinkedIn likes.
The PMCPA has dug into the industry’s LinkedIn activities once again. AstraZeneca received the harshest censure in the latest set of cases, taking a telling-off over one of its own posts, while Pfizer escaped with a slap on the wrist after its employees got too liberal with their LinkedIn likes.
